Apellis Pharmaceuticals Inc (APLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apellis Pharmaceuticals Inc (APLS) has a cash flow conversion efficiency ratio of -0.038x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.18 Million) by net assets ($370.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Apellis Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Apellis Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Apellis Pharmaceuticals Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Apellis Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apellis Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RTL Group SA
F:RRTL
|
-0.003x |
|
Motilal Oswal Financial Services Limited
NSE:MOTILALOFS
|
-0.181x |
|
Youngor Group Co Ltd
SHG:600177
|
0.020x |
|
Credito Emiliano S.p.A
F:EAO
|
N/A |
|
Inventec Corp
TW:2356
|
0.239x |
|
Changzhou Xingyu Automotive Lighting Systems Co Ltd
SHG:601799
|
0.053x |
|
Loar Holdings Inc.
NYSE:LOAR
|
0.026x |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
0.035x |
Annual Cash Flow Conversion Efficiency for Apellis Pharmaceuticals Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Apellis Pharmaceuticals Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Apellis Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $370.15 Million | $45.33 Million | 0.122x | +131.85% |
| 2024-12-31 | $228.54 Million | $-87.87 Million | -0.384x | +87.43% |
| 2023-12-31 | $194.52 Million | $-594.74 Million | -3.057x | -1.10% |
| 2022-12-31 | $169.87 Million | $-513.75 Million | -3.024x | -6.69% |
| 2021-12-31 | $198.66 Million | $-563.13 Million | -2.835x | -261.30% |
| 2020-12-31 | $204.56 Million | $-160.49 Million | -0.785x | +87.28% |
| 2019-12-31 | $34.23 Million | $-211.13 Million | -6.168x | -656.56% |
| 2018-12-31 | $160.97 Million | $-131.24 Million | -0.815x | -160.61% |
| 2017-12-31 | $148.94 Million | $-46.60 Million | -0.313x | +71.37% |
| 2016-12-31 | $23.79 Million | $-26.00 Million | -1.093x | -102.71% |
| 2015-12-31 | $34.98 Million | $-18.86 Million | -0.539x | +28.33% |
| 2014-12-31 | $13.22 Million | $-9.95 Million | -0.752x | +1.25% |
| 2013-12-31 | $4.52 Million | $-3.44 Million | -0.762x | -- |
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more